A total of 8361 patients were treated with piperacillin–tazobactam between January 2003 and June 2014; 131 (1.57%) had a documented ADR attributed to the drug. In 10 of the 131 (7.6% ...

Antimicrobial CAP treatment costs at UPMC are 2 to 3 times higher than at other similar institutions without a demonstrated benefit in clinical outcomes. These higher costs are driven by ...